NCT00918255 - Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

November 30, 2010

Conditions

Hidradenitis Suppurativa

Interventions

BIOLOGICAL

adalimumab

Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters

DRUG

Placebo

Subcutaneous injection using prefilled syringe containing 0.8 milliliters

Trial Locations (26)

2400

Site Ref # / Investigator 18683, Copenhagen NV

4000

Site Ref # / Investigator 18684, Roskilde

10016

Site Ref # / Investigator 19141, New York

10019

Site Ref # / Investigator 18208, New York

17033

Site Ref # / Investigator 18981, Hershey

19104

Site Ref # / Investigator 18464, Philadelphia

23507

Site Ref # / Investigator 18206, Norfolk

24105

Site Ref # / Investigator 18469, Kiel

27103

Site Ref # / Investigator 19001, Winston-Salem

30327

Site Ref # / Investigator 18209, Atlanta

33136

Site Ref # / Investigator 18204, Miami

35205

Site Ref # / Investigator 19062, Birmingham

47714

Site Ref # / Investigator 18211, Evansville

60077

Site Ref # / Investigator 18202, Skokie

63104

Site Ref # / Investigator 18461, St Louis

68144

Site Ref # / Investigator 18466, Omaha

78258

Site Ref # / Investigator 18463, San Antonio

90045

Site Ref # / Investigator 18467, Los Angeles

92103

Site Ref # / Investigator 18207, San Diego

93309

Site Ref # / Investigator 18201, Bakerfield

02111

Site Ref # / Investigator 18203, Boston

02114

Site Ref # / Investigator 18210, Boston

75246-1613

Site Ref # / Investigator 19061, Dallas

06847

Site Ref # / Investigator 18471, Dessau

1105 AZ

Site Ref # / Investigator 18470, Amsterdam

3015 CA

Site Ref # / Investigator 18468, Rotterdam